eCommons@AKU
Department of Biological & Biomedical Sciences

Medical College, Pakistan

January 2016

Anti-mullerian hormone: Above and beyond
conventional ovarian reserve markers
Zehra Jamil
Aga Khan University, zehra.jamil@aku.edu

Syeda Sadia Fatima
Aga Khan University, sadia.fatima@aku.edu

Khalid Ahmed
Aga Khan University

Rabia Malik
Aga Khan University

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs
Part of the Biochemistry Commons
Recommended Citation
Jamil, Z., Fatima, S. S., Ahmed, K., Malik, R. (2016). Anti-mullerian hormone: Above and beyond conventional ovarian reserve
markers. Disease Markers, 2016, 5246217.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/394

Hindawi Publishing Corporation
Disease Markers
Volume 2016, Article ID 5246217, 9 pages
http://dx.doi.org/10.1155/2016/5246217

Review Article
Anti-Mullerian Hormone: Above and Beyond Conventional
Ovarian Reserve Markers
Zehra Jamil, Syeda Sadia Fatima, Khalid Ahmed, and Rabia Malik
Department of Biological & Biomedical Sciences, Aga Khan University, P.O. Box 74800, Karachi, Pakistan
Correspondence should be addressed to Zehra Jamil; zehra.jamil@aku.edu
Received 14 October 2015; Accepted 6 January 2016
Academic Editor: Stamatios Theocharis
Copyright © 2016 Zehra Jamil et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Management of ovarian dysfunctions requires accurate estimation of ovarian reserve (OR). Therefore, reproductive hormones and
antral follicle count (AFC) are assessed to indicate OR. Serum anti-Mullerian hormone (AMH) is a unique biomarker that has a
critical role in folliculogenesis as well as steroidogenesis within ovaries. Secretion from preantral and early antral follicles renders
AMH as the earliest marker to show OR decline. In this review we discuss the dynamics of circulating AMH that remarkably vary
with sex and age. As it emerges as a marker of gonadal development and reproductive disorders, here we summarize the role of AMH
in female reproductive physiology and provide evidence of higher accuracy in predicting ovarian response to stimulation. Further,
we attempt to compile potential clinical applications in children and adults. We propose that AMH evaluation has a potential
role in effectively monitoring chemotherapy and pelvic radiation induced ovarian toxicity. Furthermore, AMH guided ovarian
stimulation can lead to individualization of therapeutic strategies for infertility treatment. However future research on AMH levels
within follicular fluid may pave the way to establish it as a marker of “quality” besides “quantity” of the growing follicles.

1. Introduction
Sexually undifferentiated embryo consists of Wolfian as well
as Mullerian ducts. In males, the testicular Sertoli cells start
secreting anti-Mullerian hormone (AMH) as early as 7th
week of gestation that leads to regression of Mullerian duct.
As a result, the Wolfian duct gives rise to epididymis and the
seminal vesicles, under the influence of testosterone. Since
then, AMH remains steady until puberty, when it rapidly
declines in response to testosterone synthesis [1]. On the
other hand, absence of AMH in female fetus allows the
Mullerian duct to give rise to uterus, fallopian tubes, and
upper part of vagina. The earliest production of AMH in
females is reported at the 36th week of gestation. At birth,
they have approximately 35 times lower AMH than males of
similar age [1]. Since then, gradual surge in the production
of AMH reflects a steady rise in the number of growing
ovarian follicles. The strong correlation of AMH with the
number of growing follicles is supported by the fact that its
levels are reported very high in ovarian tumors [2] and in
polycystic ovaries [3] while undetectable levels are testified
in postmenopausal women [4] and Turner syndrome patients

without gonadal tissue [1]. Regarding the production of AMH
in later life, a mild peak is observed at the puberty, followed
by the highest level of secretion between 23 and 25 years of
age [5]. This corresponds to the most fertile era of a female.
Afterwards, these levels steadily decline until the hormone
becomes undetectable, corresponding to menopause [5].
Over recent years, researchers have highlighted AMH as a
valid marker of ovarian ageing [6].
AMH, a homodimeric glycoprotein, is also recognized as
Mullerian inhibiting hormone (MIH). It belongs to the family
of transforming growth factor-𝛽 (TGF-𝛽) and its gene is
located on chromosome 19 p13.3, containing 5 exons [1]. The
hormone binds to its receptor (AMHR), a single transmembrane protein with serine-threonine kinase activity [7]. These
receptors are expressed on target organs such as Mullerian
ducts, Sertoli and Leydig cells of testis, and granulosa cells
of the ovary. Several genes have been identified that regulate
the production of AMH such as SF1, GATA1, WT1, DAX1, and
SOX9 [8]. AMH has been conventionally known for its role
in male sexual differentiation until the late 1990s, when it was
identified and reported for the first time in females [9].
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Figure 1: Schematic representation of hormonal surges across the follicular phase of ovarian cycle. 1: initial recruitment; 2: cyclic recruitment;
3: selection; 4: dominance; 5: ovulation. (−) non/poorly visualized; (+) well visualized. AMH is secreted by all growing follicles but its serum
levels reflect only the secretion from follicles lying close to the vascular bed. It has an inhibitory effect on steps 1 and 2, thus maintaining the
ovarian pool. The emphasis is on AMH production in early stages of follicle development as opposed to all other hormones that are released
at later stages. Follicular fluid AMH levels show a better correlation with oocyte competence and hence can prove to be a reliable marker of
embryo transfer outcomes.

2. AMH in Reproductive Physiology
2.1. Ovarian Physiology. Females are born with a fixed number of primordial follicles, resting in a dormant state of
meiosis II until puberty, until they enter different stages of
development. The quantity and the quality of primordial
follicle constitute the reserve of an ovary [10]. Due to the size
and placement of these resting follicles, direct assessment of
the pool is nonfeasible. Although these dormant primordial
follicles do not secrete AMH; however, as soon as they are
recruited for development, expression for AMH secretion is
reported [11]. Immunohistochemistry reveals that preantral
and small antral follicles measuring 2 to 8 mm express highest
amount of AMH thus making it the earliest marker of ovarian
follicular growth [12]. As soon as these follicles enter FSHdependent stages of development (8 to 10 mm size), this
expression is said to be lost [13].
AMH has a potential role in conservation of OR; it does
so by exerting dual actions. Firstly, it inhibits the initial
recruitment of follicles for growth by averting several stimulatory growth factors for recruitment such as KIT ligand and

basic fibroblast growth factor [14]. Secondly, since puberty,
AMH reduces the sensitivity of the primordial follicles to
FSH, thus decreasing their chance of cyclic recruitment [15].
Once a follicle reaches the size of around 8 mm and is
selected for dominance, AMH production rapidly declines
[12]. This supports the role of AMH as a major regulator of
initial as well as cyclic recruitment of follicles by maintaining
their threshold for FSH sensitivity (Figure 1). This is further
evident by the fact that, in AMH null mice, the greater
number of types of follicular recruitment leads to a burnout
of primordial pool at an earlier age [15].
2.2. Physiology of Menstrual Cycle. During menstrual cycle
it is observed that AMH exhibit mild fluctuation; however
this intercyclic variation is much lower than its variability
amongst individuals of the same age (also termed as interindividual variability) [16]. Although in recent times, limited studies have reported intercyclic fluctuation as these
variations are observed at random times, majority of the
researchers provide convincing evidence that AMH can be
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measured at any time throughout the cycle [17]. Mild fluctuation can be explained by the fact that dominant follicles lack
AMH production, resulting in slight decline during late follicular stage. Furthermore, interindividual variability mainly
reflects the greater difference of OR amongst individuals.
Few studies have also reported ethnic variations, suggesting
discrepancy between OR amongst different populations [18].
This fact calls for a need to establish valid baselines of AMH
levels in diverse population across the world. Currently, in
women aged 25 to 40 years, literature in terms of fertility
recommends levels of 1.0 to 3.0 ng/mL AMH as “normal,” 0.7
to 0.9 ng/mL as “low normal,” and 0.3 to 0.6 ng/mL as “low”
and less than 0.3 ng/mL is considered to be a “very low” range
[19]. With age, OR falls to a critical level, finally leading to
menopause. AMH has been successfully used in predicting
the median age to menopause well beforehand, rendering it
as the best endocrine marker to predict the age related decline
in OR [20].

3. Assessment of Anti-Mullerian Hormone:
Above and Beyond
In assisted reproductive technology (ART), optimization of
the treatment protocol and counseling of patients require
steadfast evaluation of OR. While several studies have used
various direct and indirect biochemical measures to provide
an insight, none of these fulfill the criteria of a single parameter satisfactory for OR assessment. Inhibin B and AMH are
examples of direct measures as they are produced during
follicular development, independent of follicular stimulation.
Similarly, indirect measures include FSH, LH, and estradiol,
as they rely on the production of other hormones through
a feedback loop. AFC evaluation on transvaginal ultrasound
is a reliable biophysical marker for OR estimation. With the
development of more robust and reliable laboratory methods
in recent times, AMH is being extensively investigated. Its
assessment has several advantages over other biochemical
and biophysical markers. Here we have briefly discussed the
traditional ovarian markers and have compiled evidence to
support the larger role of AMH as opposed to others.
3.1. Follicle Stimulating Hormone (FSH). Traditionally, FSH
has been the OR biomarker of choice. It is well studied, documented, and validated and thus provides a level of comfort
to physicians. Since the late 1980s, it is being used to indicate
hypothalamic-pituitary-gonadal axis functioning. Currently,
World Health Organization classifies ovarian dysfunction on
the bases of serum FSH and estradiol levels [21]. Testing is
available on multiple automated platforms being relatively
fast, inexpensive, and reproducible. FSH fluctuates with the
menstrual cycle; therefore the samples are collected on day
3 of menstrual cycle to reflect the basal level. As women
and their follicles age, FSH rises in reaction to decreased
responsiveness of ovary [22].
Even though FSH is the most widely recognized ovarian
marker, yet it may not be the best option. For instance, it
exhibits both inter- and intracyclic fluctuations; thus single
day 3 FSH measurement may fail to be an accurate marker,
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suggesting evaluation of subsequent cycle’s day 3 FSH [23].
Secondly, the assessments of FSH, estradiol, and Inhibin
B all suffer from low sensitivity in the initial stages of
diminished OR, only becoming abnormal once the reduction
in reserve is critically low. Any fertility assistance at this
stage of OR may hardly improve the chances of assisted
pregnancy [24]. Thirdly, it is affected by several conditions
(other than ovarian causes). Therefore, FSH levels are raised
in patients receiving hormonal therapy, oral contraceptive
pills, and pituitary tumors and in patients with Turner
syndrome even in the presence of optimum OR [25, 26]. In
contrast, lower levels of FSH are observed in nonovulatory
polycystic ovarian syndrome (PCOS) and nonfunctioning
pituitary tumors [27, 28]. In all such cases, FSH does not
reflect OR consistently; however AMH still reflects the true
reserve being independent of hypothalamic axis feedback
loop.
These weaknesses can be resolved by assessment of
AMH since it stands as the “cycle-independent” marker that
remains steady throughout the menstrual cycle [29]. Furthermore, it has emerged as an early indicator of decreased OR as
decline in AMH level is reported parallel to drop in the OR.
This makes it ideal for screening and timely referring patients
to ART clinics [6]. Regarding prediction of menopause, rise
in FSH levels, estimation of AFC, and decline in AMH all
show significant correlation; however numerous researches
have observed greater strength of AMH and AFC as opposed
to FSH in this regard [6]. Though FSH has an established role
in ART, recent advances highlight the strengths of AMH to fill
in gaps encountered with FSH evaluation as an OR marker.
3.2. Luteinizing Hormone (LH). Luteinizing hormone is a
glycoprotein, secreted by the anterior pituitary gland. It has a
decisive role in ovarian steroidogenesis and ovulation. It progressively increases across the follicular phase of menstrual
cycle and peaks at the time of ovulation [30]. LH receptors are
more sparsely located on dominant follicle than the smaller
follicles, allowing them to continue growing, compared to
others [30]. These antral follicles under the influence of LH
rapidly synthesized estradiol, essential for oocyte maturation
and endometrium readiness for implantation. It is also
required for priming of the hypothalamic-pituitary-ovarian
axis for successive LH surge required for ovulation induction
[31].
This physiological mechanism has prompted its use in
assessment of ovarian functions. In 1998, basal day 3 LH
concentrations of less than 3 mIU/mL were reported to
be the earliest evidence of prediction for a poor ovarian
response in ART [32]. Interestingly since then, most of the
researchers have found a lack of association between LH
concentration and prediction of OR and ART outcomes. In
addition, its intra- and intercyclic fluctuation also decrease
the power of reproducibility. In patients with PCOS, raised
levels of LH are often reported, rendering LH/FSH ratio
assessment as a sensitive marker to diagnose PCOS [33]. On
the contrary, there is a much stronger evidence of correlation
amongst raised AMH and PCOS, as the number of AMH
secreting small antral follicles is significantly increased in
PCOS [3]. Moreover, specificity and sensitivity of serum
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AMH in predicting OR in general and the response of ART
in particular stand much higher than LH as well as FSH/LH
ratio [34]. In a nutshell, in comparison to AMH, LH has a
feeble association with ovarian pool and follicular growth as
well as response to ovarian stimulation.
3.3. Inhibin B. Inhibin B, a heterodimeric glycoprotein, exerts
its negative feedback effect on FSH secretion from the pituitary gland, potentiating FSH withdrawal from nondominant
follicles [35]. Both AMH and Inhibin B are secreted from the
granulosa cells of primary, secondary, and early antral follicles
and represent the size of GnRH-reactive antral follicles. To
provide a reliable interpretation, Inhibin B is assessed on the
same day of cycle (days 2 to 5), as it peaks in early follicular
phase and declines to nondetectable levels during luteal phase
[36]. Prediction of menopause is critical in older patients
who are willing to undergo assisted infertility treatment.
Although, Inhibin B levels drastically fall with age, they are
less predictive of menopause. On the contrary, researchers
suggest that AMH can accurately reflect this transition up to
five years prior to finally attaining menopause [37].
Inhibin B has also been studied to predict the outcomes of
ART. Conversely, no added advantage has yet been confirmed
over FSH as well as AMH, in assessing poor response
or ovarian hyperstimulation syndrome (OHSS), number of
oocytes retrieved or pregnancy outcomes [38]. Even in PCOS,
its levels remain within normal limit, excluding it as a marker
of increased follicular growth [38]. It is noteworthy that, in
young cancer patients receiving ovarian toxic chemotherapy,
Inhibin B and estradiol remain unchanged while AMH
falls drastically, with a modest rise in FSH level [39]. Thus
chemotherapy induced ovotoxicity is most consistently indicated by assessment of AMH levels.
3.4. Estradiol (E2). Estradiol is a steroid sex hormone, produced by the ovarian follicles as well as adipose, liver, adrenal,
breast, and neural tissues [40]. Due to its multiple sites
of secretion, it is never evaluated as a solo marker. It is
worth mentioning that E2 might be decreased in estrogenproducing tumors and elevated due to precocious puberty,
falsely being interpreted for ovarian status [41]. The secretion
of E2 by the early antral follicles is under the influence of FSH
led hypothalamic dependence, that is, feedback-dependent.
E2 has been used to monitor OR in women with amenorrhea or menstrual dysfunction and to detect the state
of hypoestrogenism and menopause. Furthermore, estrogen
monitoring is considered useful to assess follicular growth
during fertility therapy. There are mixed reports relating
elevated basal E2 levels and a poor ovarian response; however few studies have established correlation between poor
ovarian response and E2 levels of <20 or >80 pg/mL [42].
Although the levels of circuiting E2 had been successfully
used in decreasing the incidence of OHSS, high serum levels
of AMH are more strongly associated with OHSS [43].
These findings lead to the conclusion that while comparing the pit falls and clinical applicability of AMH, basal
estradiol has a very low predictive accuracy, for both ovarian
responsiveness and pregnancy outcomes. AMH being solely
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secreted by ovaries as well as devoid of the feedback loop
fulfills the criterion of “autonomous analyst of OR.”
3.5. Antral Follicle Count (AFC). Antral follicle count is
considered as most reliable method to evaluate the ovarian
response; however it suffers from operator variability as well
as mechanical inconsistency. Even with the same operator,
AFC has higher intra- and intercycle variability [44]. It is
preferably assessed in early follicular stage, as the presence
of larger follicles or corpus luteum interferes in accurate
visualization and estimation. As transvaginal ultrasound
(TVS) does not differentiate between healthy and atretic
follicles, it counts both as capable of responding to treatment
[45]. To utilize the real potential of AFC, it is essential to
invest in technology as well as training of the staff, in order
to obtain accurate clinical interpretation. Furthermore, TVS
is not a suitable technique in females with previous ovarian
surgeries or ovarian cysts, as they hinder in visualization
of small follicles [45]. It is noteworthy that both AFC and
AMH appear to be valuable indicators. Studies suggest that
AMH relates well with the basal AFC and thus are considered
interchangeable [6]. As blood tests clearly have marked
advantages over ultrasound for primary care physicians,
AMH has a greater efficiency over AFC, especially in setups
where high class technology is not available.
In the context of ART, AFC is used in routine to monitor
the ovarian responses. Different studies have taken various
counts to define normal AFCs (10 ± 4 follicles); thus absence
of a standard cutoff or uniform measurement criteria has
hampered in accurate clinical interpretation [46]. On the
other hand, threshold values of AMH, ranging from 0.2 to
1.26 ng/mL, have been used to identify poor responders with
80–87% sensitivity and 64–93% specificity [47]. AMH may be
considered as more sensitive probe to identify early follicles
measuring 0.4 to 2 mm, as they are not visualized on TVS.
In ovarian stimulation, a combined evaluation of AFCs and
AMH has successfully led to prediction of poor as well as
hyperresponsiveness [48]. This has opened new horizon to
individualized infertility treatment in order to maximize the
chance of pregnancy and eliminate iatrogenic side effects for
each patient [48].
To summarize, both AFC and AMH have clinical value
in providing useful information regarding OR as well as
responsiveness to treatment. AMH more accurately reflects
very small and nonatretic follicles, reflecting a true picture of
OR while AFC helps to visualize the size of growing follicles,
crucial to analyze the progress of stimulation. It is clearly
evident that analysis of multiple markers has significantly
improved predictive accuracy of ART outcomes (Table 1).

4. Possible Clinical Applications of AMH
4.1. Pediatrics Disorders of Sex Development. AMH has
emerged as a marker of gonadal development and reproductive disorders in pediatric age group. As discussed earlier, along with testosterone, it plays an essential role in
sex differentiation and the normal development of testes.
Its absence or lower levels in males suggest dysfunctional
testis while in female, its presence in higher concentration
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Table 1: Comparison of characteristics of the most widely used
markers of ovarian reserve (modified with permission from La
Marca et al. [44, 47]).
Characteristics of a good
marker

Age

AMH

FSH

AFC

Low intercycle variability

+++

+++

−

++

Low intracycle variability

+++

++

−

++

Applicable to all patients

+++

+++

+

+

Operator independency

+++

+++

+++

−

Prediction of poor response

+

+++

++

+++

Prediction of hyper
response
Prediction of oocyte
retrieval
Individualization of
treatment
Economics

+

+++

+

+++

++

+++

+

+++

+

+++

−

+++

+++

−

−

−

−: not appropriate, +: not very appropriate, ++: appropriate, and +++: very
appropriate.

indicates existence of testicular tissue [1]. Currently, AMH
is being used to determine the presence of testicular tissue
in conditions such as ambiguous genitalia, anorchia, or
cryptorchidism [49]. In Klinefelter syndrome, it indicates the
severity of testicular dysfunction [50]. In children treated
for ovotestis, AMH has the potential of being a diagnostic
marker for identifying the presence of testicular tissue, before
and after surgical intervention [51]. Moreover, it may assist
in differentiating between various causes of virilization in
girls. AMH is found to be raised in granulosa cell tumor
or testicular tissues induced virilization while it is normal
in virilization caused by congenital adrenal hyperplasia [1].
Turner syndrome patients are prone to be at a higher risk
of accelerated OR loss; monitoring of AMH in such cases
seems to be an excellent indicator of premature ovarian
insufficiency, suggesting timely interventions [52].
4.2. Obesity Associated Infertility. Obesity affects one-fifth
of the female population, with 18.3% belonging to the
reproductive age group (16–44 years) [53]. Prevalence of
infertility is higher in obese women due to decreased OR as
well as follicular dysfunction [54]. Although its underlying
mechanism is not well understood, it is hypothesized that low
levels of adiponectin (adipocytokine) stimulate aromatase
activity in the ovary [55]. As a result, AMH production
falls, reflecting dysfunctional folliculogenesis. A number of
studies have reported significant relationship between low
levels of AMH and higher body mass index (BMI) while
few studies reported lack of relationship [53]. This might
be due to the fact that the obese patients suffering from
underlying pathology such as PCOS have a much higher level
of AMH, giving a false overall picture. This fact should be
deemed as strength of AMH that truly reflects the status of
the ovarian reserve without being influenced by conditions
such as obesity.

4.3. Assisted Reproductive Technology. Age, FSH, LH, estradiol, Inhibin B, AFC, and ovarian volume have been conventionally used to assess ovarian function for years. These
parameters assist in protocol selection and counseling of
patients. In the last decade AMH has emerged superior to
other markers of OR. As AMH has a significantly better
predictive value than FSH and AFC, especially in women
over 38 years, AMH evaluation is beginning to establish its
place in baseline investigation prior to ovarian stimulation
[56]. Infertility clinics are increasingly analyzing patient’s age
with AMH to design individualized stimulation protocol. In
clinical practice, AMH evaluation has guided infertility care
physicians to modify the dose of medication, avoiding the risk
of OHSS or cycle cancellation due to nonresponsiveness [57].
However, it is important to understand that although AMH is
a reliable predictor of ovarian response, yet researches report
a lack of predictive accuracy for pregnancy outcomes. This
might be due to the fact that it indicates the quantity of the
follicle but does not rule out the chance of “compromised
quality” [45]. Therefore, patients with higher AMH may still
fail to conceive while positive pregnancies have been reported
in patients with extremely low AMH [58]. In the recent
times, AMH levels within ovarian follicular fluid have been
strongly associated with the pregnancy rates in IVF (in vitro
fertilization) treatment [2]. In a nutshell, AMH is a useful tool
to predict and evaluate the efficacy of the treatment but it has
a limited clinical use as a marker of pregnancy outcomes.
4.4. Polycystic Ovarian Syndrome (PCOS). PCOS is the most
common cause of anovulatory infertility, affecting 10 to 15%
women of reproductive age [59]. In various parts of the
world, PCOS is currently being diagnosed on the basis of
Rotterdam criteria which diagnoses the syndrome on the
presence of at least two of the following three features:
hyperandrogenism, oligomenorrhea, and polycystic ovaries
[60]. In recent years, it has been reported that, in PCOS,
AMH levels are elevated up to two- to threefold, reflecting the
load of growing follicles [61]. This correlation with follicular
growth implies the strength of AMH as a marker of severity of
ovarian dysfunction and hyperandrogenism in women with
anovulatory PCOS [61]. In the light of current literature,
it seems that AMH will soon secure a place in Rotterdam
criteria as a diagnostic marker for PCOS [62].
4.5. Chemotherapy and Radiotherapy Induced Ovarian Damage. Groundbreaking advancements in cancer treatment
have paved the way to improved survival rates, highlighting the importance to preserve an optimal quality of life
after treatment. Ovaries are considered as a major target
of xenobiotic which specifically affect the growing follicles.
Xenobiotics cause infertility, a worrisome consequence in
childhood cancer survivors and women of reproductive age
[10]. The pre- and posttreatment analysis of AMH give a
useful picture of the damage caused by chemotherapy or
pelvic radiation. Similarly, AMH after treatment evaluation
also reflects the recovery of gonadal function on completion
of the treatment [63]. On the bases of AMH monitoring,
timely referral to reproductive endocrinologist can assist
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Table 2: Summary of available evidence for clinical applications of anti-Mullerian hormone.

Year

Author

Sample
size

Study

2013

Fleming et al.
[66]

𝑛 = 683
PCOS

Meta-analysis

2011

Karkanaki et
al. [2]

Review

2013

Lindhardt
Johansen et
al. [1]

Review

2011

Yates et al.
[57]

2014

Broer et al.
[21]

Case
𝑛 = 423
Control
𝑛 =346

Retrospective

Review

Outcomes
AMH value of 4.7 ng/mL has the power to diagnose PCOS with
(i) 79.4% specificity and 82.8% sensitivity & AUC = 0.87 (95% CI
0.83–0.92)
Decreased AMH in
(i) Ageing, higher BMI, ovariectomy, chemo/radio therapy, GnRH
administration, pregnancy, and oral contraceptive pills
Raised AMH in polycystic ovarian syndrome
Diagnostic role of AMH in pediatric group includes the following:
(i) Determination of testicular tissue
(ii) Persistent Mullerian duct syndrome
(iii) Females with virilization and polycystic ovaries
(iv) Premature ovarian insufficiency
(v) Hypogonadotropic hypogonadism
(vi) Klinefelter syndrome
(vii) Granulosa cell tumor
AMH tailor individualized ovarian stimulation significantly
(i) Increased embryo transfer (79–87%) and live birth rates (15.9–23.9%)
(ii) Decreased OHSS (6.9 to 2.3%) and failed fertilization (7.8 to 4.5%)
(iii) Reduced cost of fertility treatment by 29% per patient
Novel indications for use of AMH for ovarian reserve testing in
(i) Small for gestational age
(ii) Type I diabetes mellitus
(iii) Autoimmune diseases like lupus erythematous
(iv) Ovarian surgery and uterine artery embolization for fibroids
(v) BRCA 1/2 mutation carriers

childhood cancer survivors in their puberty progression.
Donation of ovum is prohibited in various countries; thus
AMH is a relevant marker to screen women at a higher risk of
developing chemotherapy induced infertility, referring them
well in time for ART consultation and fertility preservations.
4.6. Ovarian Tumors. In 1992 AMH was identified as the
marker of ovarian tumors of granulosa cell origin. As it is
exclusively secreted by granulosa cells, it is a reliable marker
for diagnosis as well as monitoring for recurrences of tumor.
Raised levels have been found in 76 to 93% of women with
granulosa cell tumors [2]. Moreover, AMH surge is observed
up to 16 months prior to clinical recurrence of the tumor itself,
suggesting it as a useful marker of granulosa cell activity [64].
As AMH induces regression of Mullerian duct in fetal
life, lately in vitro studies have highlighted its inhibitory role
in epithelial cell ovarian cancers [65]. This seems to be a
beginning of the newer role of AMH as a therapeutic and/or
diagnostic agent (Table 2).

makes it a timely and reliable indicator. In developing countries, AMH evaluation is presently not included in the baseline assessment preceding ovarian stimulation in ART, but in
the light of reviewed evidence we propose that inclusion of
AMH evaluation can essentially lead to individualization of
therapeutic strategy, minimizing iatrogenic effects as well as
the liability of the cost. As with conventional OR markers,
AMH has low predictive accuracy for live births. Pregnancies
have even been reported with very low AMH, indicating its
inability to reflect on the quality of oocyte. Hence its use in
ART should be aimed for effective designing of protocol and
counseling, at the same time keeping in mind that patients
should not be deprived of treatment on the ground of very low
AMH. Further research on the significance of varying levels
of AMH within follicular fluid may pave the way to establish
it as a marker of “quality” besides quantity of the growing
follicles.
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5. Conclusion
AMH initially considered as a male hormone has emerged
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an autonomous marker reflecting “acyclic ovarian activity.”
Strong correlation with follicle numbers, operator independency, and accurate prediction of reproductive lifespan
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